ALT · Altimmune Inc

-

Please sign in to comment on ALT

1 Comment

Admin

4 years ago

Altimmune, Inc is currently in a long term downtrend where the price is trading 35.4% below its 200 day moving average.

From a valuation standpoint, the stock is 96.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 43.9.

Altimmune, Inc's total revenue rose by 301.7% to $2M since the same quarter in the previous year.

Its net income has dropped by 159.3% to $-11M since the same quarter in the previous year.

Finally, its free cash flow fell by 576.3% to $-14M since the same quarter in the previous year.

Based on the above factors, Altimmune, Inc gets an overall score of 2/5.

Exchange	NASDAQ
CurrencyCode	USD
Sector	Healthcare
Industry	Biotechnology
ISIN	US02155H2004

Beta	0.89
Market Cap	383M
PE Ratio	None
Target Price	22.375
Dividend Yield	None

ABOUT

Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 and is headquartered in Gaithersburg, Maryland.

ALT · Altimmune Inc

-

Altimmune Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Altimmune Inc using a moving average strategy